Insurance standards set
Life Offices Association of South Africa, the association of insurance companies
in South Africa, announced a new policy to assess CFIDS disability claims. The policy will use the internationally
for CFIDS and fibromyalgia (FM) and disability will be assessed using a battery of tests. The announcement
is newsworthy for people with CFIDS worldwide because a group of insurance companies recognized that CFIDS
is disabling and compensable.
FM/CFIDS patent issued
Bentley Pharmaceuticals says it signed a
license with Dartmouth
College to obtain exclusive rights to a patent covering androgen therapy.
The Dartmouth patent
covers a variety of androgenic steroids, including testosterone, dehydroepiandrosterone (DHEA), and other
compounds used in treating CFIDS/FM.
A preliminary study conducted by Dartmouth scientists indicated
that FM patients demonstrated improved muscle function, energy levels, and restorative sleep in response
to the therapy. Copies of the press
release can be found on the company’s Web site.
Staying employed easier in future
The Department of Health and
(DHHS) announced two initiatives in late 2000 to help people with disabilities work without fear of losing
their Medicare, Medicaid, or other health benefits.
One of the programs will fund demonstrations
that will enable people with chronic, disabling conditions to get medical benefits without having to quit
their jobs if they need medical care.
The other program will assist states in increasing services
and support to disabled people who work as well as helping others return to work. For
additional information, visit DHHS’ Web site.
The Arthritis Foundation honored Dr. Daniel
Clauw with the
Breakthroughs in Research Award for his research of arthritis-related disorders associated with diffuse
pain, including CFIDS.
is the Scientific Director of the Georgetown Chronic Pain and Fatigue Research
Center and the Chief of the Division of Rheumatology, Immunology, and Allergy at
Georgetown University Medical Center.